Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers
Authors
Yap, T AKrebs, Matthew G
Soria, JC
Ross, G
Stephens, C
Khan, M
Berges, A
Im, S A
Castanon-Alvarez, E
Postel-Vinay, S
Bang, Y J
Carter, L
Sundar, R
Harrington, K
Abida, W
El-Khoueiry, A
Affiliation
Royal Marsden Hospital and The Institute of Cancer Research,Drug Development Unit, London,Issue Date
2016